Home > Press > Rice, M. D. Anderson Win Funds for 'Bench to Bed' Training
Abstract:
HHMI Program To Offer Rice Bioengineers Firsthand Training at M. D. Anderson
Rice University, The University of Texas M. D.
Anderson Cancer Center and the Howard Hughes Medical Institute (HHMI) today
announced the creation of an innovative new Ph.D. training program that will
offer Rice bioengineering students a chance to go on clinical rounds and
take coursework at M. D. Anderson.
"Over the last 50 years, there have been tremendous advances in our
understanding of the molecular and cellular processes of cancer, and great
progress in the treatment of a number of neoplastic disorders; however,
there has been no change in the age-adjusted mortality due to cancer," said
Rebecca Richards-Kortum, the principal investigator on the project and the
chair of Rice's Department of Bioengineering. "We need to revolutionize the
way we translate our knowledge of cancer biology into new technologies for
detecting and treating cancer, and with HHMI's help we'll be doing that."
Rice and M. D. Anderson's program involves a unique training program for
bioengineering Ph.D. students that integrates courses in cancer biology,
clinical medicine, bioengineering and translational research; unique
internships in clinical cancer care and translational research; and jointly
mentored inter-disciplinary Ph.D. projects. The program marries Rice's
bioengineering Ph.D. program - ranked among the nation's 10 best - with the
clinical and basic science strengths of M. D. Anderson - one of the nation's
top-ranked cancer hospitals.
The new program, "Translational Bioengineering for Cancer Diagnostics and
Therapeutics," is funded by a four-year, $850,000 award from HHMI. Rice's
program is one of 13 pioneering new translational medical research programs
funded today by HHMI's "Med to Grad" initiative, supporting innovative
graduate programs that introduce Ph.D. students to the world of clinical
medicine.
Rice's program will build upon four joint areas of research that already
exist between Rice and M. D. Anderson: computational bioengineering for
design of cancer inhibiting drugs and vaccines; molecular imaging for early
cancer detection; nanobiotechnology to design new cancer imaging and
therapeutic agents; and cell and tissue engineering to develop effective
reconstructive procedures following tumor resection.
Starting this fall, Rice will enroll seven Ph.D. students per year in the
program. The students will complete courses taught jointly by M. D. Anderson
and Rice faculty, and they will complete an intensive clinical cancer
internship that rotations at M. D. Anderson in diagnostic imaging, surgery,
radiotherapy, internal medicine, lab medicine, pathology, bone marrow
transplantation and cancer prevention. The students will also carry out a
translational research rotation that is co-supervised by faculty at both
institutions.
"In designing and implementing this program, we're bringing together an
outstanding group of faculty dedicated to translational research and
education," said Dr. Michele Follen, director of M. D. Anderson's Center for
Biomedical Engineering and professor of gynecologic oncology.
Richards-Kortum, Rice's Stanley C. Moore Professor of Bioengineering, said,
"Rice is one of only two institutions without a medical school to win an
HHMI grant under this program. This win is a testament both to the strength
of Rice's and M. D. Anderson's partnership and to the caliber of their
combined programs."
About Rice University:
Rice University is consistently ranked one of America's best teaching and research universities. It is distinguished by its: size: 2,850 undergraduates and 1,950 graduate students; selectivity: 10 applicants for each place in the freshman class; resources: an undergraduate student-to-faculty ratio of 6-to-1, and the fifth largest endowment per student among American universities; residential college system, which builds communities that are both close-knit and diverse; and collaborative culture, which crosses disciplines, integrates teaching and research, and intermingles undergraduate and graduate work. Rice's wooded campus is located in the nation's fourth largest city and on America's South Coast.
For more information, please click here
About the University of Texas M.D. Anderson Cancer Center:
The University of Texas M.D. Anderson Cancer Center is one of the world's
most respected centers devoted exclusively to cancer patient care, research,
education and prevention. Created in 1941 as a component of The University
of Texas System, M.D. Anderson is one of the nation's original three
Comprehensive Cancer Centers designated by the National Cancer Act of 1971,
and is one of 39 such centers today. M. D. Anderson employs more than 15,000
people, 1,069 of whom are M.D.s and Ph.Ds.
For more information, please click here
About the Howard Hughes Medical Institute:
The Howard Hughes Medical Institute (HHMI) is a nonprofit medical research
organization that employs hundreds of leading biomedical scientists working
at the forefront of their fields. Through its grants program and other
activities, HHMI is helping to enhance science education at all levels and
maintain the vigor of biomedical science worldwide. The Institute is one of
the world's largest philanthropies, with laboratories across the United
States and grants programs throughout the world. Its headquarters and
conference center are located in Chevy Chase, Maryland, near Washington,
D.C. HHMI's endowment in fiscal year 2004 was approximately $12.8 billion.
For more information, please click here
Contact:Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over 14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||